Prosecution Insights
Last updated: November 04, 2026
Application No. 18/338,605

METHOD FOR SCREENING INDIVIDUAL TUMOR NEOANTIGEN PEPTIDE, AND VACCINE FORMULATION THEREOF

Final Rejection §101§102
Filed
Jun 21, 2023
Priority
Mar 08, 2021 — CN 202110251383.X +1 more
Examiner
CHANDRA, GYAN
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hangzhou Neoantigen Therapeutics Co. Ltd.
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
721 granted / 1012 resolved
+11.2% vs TC avg
Strong +28% interview lift
Without
With
+27.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
38 currently pending
Career history
1051
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
31.7%
-8.3% vs TC avg
§102
15.0%
-25.0% vs TC avg
§112
30.6%
-9.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1012 resolved cases

Office Action

§101 §102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response filed on 8/18/2026 is acknowledged and fully considered. Status of Application, Amendments, And/Or Claims The amendments of claim 1 and the addition of claims 12-13 have been made of record. Claims 2-4 are cancelled. Claims 1 and 5-13 are pending. Claims 6-11 remain withdrawn for being drawn to a non-elected invention (i.e., Group II) and the withdrawn claims should be cancelled. Claims 1, 5 and 12-13 are under examination. Response to Arguments Claim Rejections - 35 USC § 102/103-withdrawn The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The rejection of claim(s) 1-5 are rejected under 35 U.S.C. 102(a) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Fang et al. (IDS, Clin. Cancer Res. 2020, 26: 4511-20) is withdrawn in view of applicant’s declaration under 37 CFR 1.130(a) that Fan Mo, Ning Han and Liang Liu are joint inventor of the instant application and the reference Fan et al. (along with co-authors) was made less than one year before the effective filing date of the instant application. Claim Rejections - 35 USC § 101-maintained 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1 and 5 remain rejected and claims 11-12 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a screening method for an individualized tumor neoantigen using a mutation frequency (Ag) of the mutation producing neoantigen at a genome level, a mutation frequency Ar of the mutation producing the neoantigen at a transcriptome level, expression level E of a gene, a number H of amino acid changes caused by the mutation, quality index Mi and Mii of epitope sequence of MHC protein type I and MHC protein type II and the uses a mathematical formula iNeo_Score: f1(Ag)x f2(Ar) x f3(E) x f4(Mi) x fs(H) + f6(Mi) without significantly more. For the reasons of record at pg.5-6 of the office action of 5/18/2026 and as discussed below. Applicants argue that in Prong Two, the examiner should evaluate whether the claim as a whole integrates the recited judicial exception into a practical application of the exception. They argue the evaluation is performed by (1) identifying whether there are any additional elements in the claim beyond the judicial exception and (2) evaluating those additional elements can integrate the exception into a practical application. They argue that claim 1, steps 5 and 6 are concrete, implementable laboratory procedures encompassing peptide synthesis, purification, lyophilization, HPLC analysis and gel chromatography. They argue that these steps translated abstract computational results into tangible products qualifying for substantially further practical applications that should satisfy the statutory eligibility criteria. They argue that steps 5 and 6 are not routine because peptide synthesis preparation introduces a specific stability screening protocol for 1-2 weeks storage at 4 °C followed by purity retesting to identify unstable peptides upfront. They argue that step 6 implements algorithm based HPLC retention time spacing, uniform cysteine distribution and solubility verification to solve the specific problem of stability, purity solubility of individualized multi-peptide vaccine formulation. Applicants arguments have been fully considered but they are not persuasive because the examiner did analyze the claim as whole and Prong two Step A is a process claim and not directed to judicial exception. However, use of algorithm to assign values to Ag, Ar, E, Mi, H, Mii to determine iNeo Score (steps 2-4) and selecting peptides for synthesis which can be automated, purified using HPLC, storing peptide for a certain period of 1-4 weeks at 4 °C followed by purity retesting or visually looking by eye (mental step) are routine in the art of peptide synthesis and purification. These steps do not add up to substantially more and peptide synthesis and purification are routine in the art (see US Pub. No. 20160310584 (paragraph [0144]). The instantly claimed method does not result in a particular method of designing and formulation of vaccine that works in practice. Therefore, the rejection is maintained. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GYAN CHANDRA whose telephone number is (571)272-2922. The examiner can normally be reached Mon-Friday 8:30AM-5:00P. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GYAN CHANDRA/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Jun 21, 2023
Application Filed
May 18, 2026
Non-Final Rejection mailed — §101, §102
Aug 18, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §101, §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780892
LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE
3y 11m to grant Granted Nov 03, 2026
Patent 12779036
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
3y 4m to grant Granted Nov 03, 2026
Patent 12767697
GIP AND GLP-1 DUAL AGONIST POLYPEPTIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT AND APPLICATION THEREOF
4y 6m to grant Granted Oct 20, 2026
Patent 12760082
GROWTH HORMONE FUSION PROTEIN AND PREPARATION METHOD AND USE THEREOF
3y 7m to grant Granted Oct 13, 2026
Patent 12742000
INSULIN-FC FUSION PROTEINS AND METHODS OF USE TO TREAT CANCER
3y 4m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+27.6%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1012 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month